<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">31875943</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>07</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1365-2133</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>182</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>The British journal of dermatology</Title>
          <ISOAbbreviation>Br J Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Pachyonychia congenita and botulinum toxin.</ArticleTitle>
        <Pagination>
          <StartPage>531</StartPage>
          <EndPage>532</EndPage>
          <MedlinePgn>531-532</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/bjd.18784</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Thomas</LastName>
            <ForeName>B R</ForeName>
            <Initials>BR</Initials>
            <Identifier Source="ORCID">0000-0002-1815-3502</Identifier>
            <AffiliationInfo>
              <Affiliation>Centre for Cell Biology and Cutaneous Research, The Blizard Institute, Barts and the London School of Medicine and Dentistry, 4 Newark Street, London, E1 2AT, U.K.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Barts Health NHS Trust, Whitechapel Road, London, E1 1BB, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sahota</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Barts Health NHS Trust, Whitechapel Road, London, E1 1BB, U.K.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016420">Comment</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Br J Dermatol</MedlineTA>
        <NlmUniqueID>0004041</NlmUniqueID>
        <ISSNLinking>0007-0963</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 3.4.24.69</RegistryNumber>
          <NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentOn">
          <RefSource>Br J Dermatol. 2020 Mar;182(3):671-677</RefSource>
          <PMID Version="1">31127950</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001905" MajorTopicYN="Y">Botulinum Toxins</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002985" MajorTopicYN="N">Clinical Protocols</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007057" MajorTopicYN="Y">Ichthyosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007645" MajorTopicYN="Y">Keratoderma, Palmoplantar</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053549" MajorTopicYN="Y">Pachyonychia Congenita</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>27</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31875943</ArticleId>
        <ArticleId IdType="doi">10.1111/bjd.18784</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>References</Title>
        <Reference>
          <Citation>Swartling C, Vahlquist A. Treatment of pachyonychia congenita with plantar injections of botulinum toxin. Br J Dermatol 2006; 154:763-5.</Citation>
        </Reference>
        <Reference>
          <Citation>Goldberg I, Sprecher E, Schwartz ME, Gaitini D. Comparative study of high-resolution multifrequency ultrasound of the plantar skin in patients with various types of hereditary palmoplantar keratoderma. Dermatology 2013; 226:365-70.</Citation>
        </Reference>
        <Reference>
          <Citation>Brill S, Sprecher E, Smith FJD et al. Chronic pain in pachyonychia congenita: evidence for neuropathic origin. Br J Dermatol 2018; 179:154-62.</Citation>
        </Reference>
        <Reference>
          <Citation>Koren A, Sprecher E, Reider E, Artzi O. A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita-associated keratoderma. Br J Dermatol 2020; 182:671-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Maiaru M, Leese C, Certo M et al. Selective neuronal silencing using synthetic botulinum molecules alleviates chronic pain in mice. Sci Transl Med 2018; 10:eaar7384.</Citation>
        </Reference>
        <Reference>
          <Citation>Grando SA, Zachary CB. The non-neuronal and nonmuscular effects of botulinum toxin: an opportunity for a deadly molecule to treat disease in the skin and beyond. Br J Dermatol 2018; 178:1011-19.</Citation>
        </Reference>
        <Reference>
          <Citation>Swartling C, Karlqvist M, Hymnelius K et al. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol 2010; 163:1072-6.</Citation>
        </Reference>
        <Reference>
          <Citation>Gonzalez-Ramos J, Sendagorta-Cudos E, Gonzalez-Lopez G et al. Efficacy of botulinum toxin in pachyonychia congenita type 1: report of two new cases. Dermatol Ther 2016; 29:32-6.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
